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STAT3 playsmany roles in tumorigenesis. In this issue ofCancer Cell, Kortylewski et al. show that in the tumor
microenvironment, STAT3 enhances the expression of the protumor cytokine IL-23 in macrophages but
inhibits the antitumor cytokine IL-12 in dendritic cells. STAT3 also mediates IL-23’s effect of activating
tumor-infiltrating regulatory T cells.The transcription factor STAT3 is overex-
pressed in tumor cells, stromal cells, and
infiltrating hematopoietic cells of many
types of tumors. When overexpressed in
tumor cells, STAT3 contributes to their
survival, proliferation, and dissemination.
STAT3 activation favors proliferation of
malignant cells by exerting an antiapop-
totic effect, in part mediated by transcrip-
tional downregulation of p53, and by
inducing factors that drive angiogenesis
and metastasis including VEGF and met-
alloproteases. Overexpression of STAT3
in tumors also has a major effect on
recruiting tumor-infiltrating hematopoietic
cells by controlling production of chemo-
tactic factors and the expression of
their receptors by infiltrating cells. Many
factors released by the tumor and the
tumor stroma, such as VEGF, inter-
leukin-6 (IL-6), and IL-10, can play a role
in STAT3 overexpression. Interestingly,
several of these factors are themselves
transcriptionally regulated by STAT3,
thus creating a positive feedback regula-
tion of their production (Yu et al., 2007).
Although STAT3 activation induces
recruitment of hematopoietic cells, STAT3
activation in tumor-associated macro-
phages (TAMs) and dendritic cells (DCs)
has a profound anti-inflammatory effect
by preventing their complete maturation
and blocking their ability to produce
many proinflammatory cytokines such as
IL-12 (El Kasmi et al., 2007; Yu et al.,
2007). These contrasting activities are
well suited for tumor growth because
proinflammatory cells provide factors for
stromal development and angiogenesis
but strong inflammatory responses with
antitumor and antiangiogenic effects areprevented. Indeed, progressing tumors in
humans and experimental animals are
characterized by the presence of infil-
trating immature and anergic TAMs and
DCs and a limited infiltration of T lympho-
cytes that often have the characteristic of
regulatory T cells (Tregs). Through the
production of IL-10 and TGF-b or direct
cellular contacts, Tregs contribute to inac-
tivation of antigen-presenting cells and
suppress proliferation and antitumor
activity of effector T cells, including IFN-
g-producing cells (Th1 cells) and cytotoxic
T lymphocytes (CTLs) with antitumor
activity (Zou, 2006).
Cytokines of the IL-12 family shape and
control the outcome of inflammatory
processes (Trinchieri et al., 2003). IL-12
is a heterodimeric cytokine composed of
two covalently linked chains, IL-12a
(p35) and IL-12b (p40). The IL-12 receptor
is also composed of two chains, IL-12Rb1
and IL-12Rb2, which link to the kinases
Tyk2 and Jak2 and signal prevalently
through activation of STAT4. The main
immunological functions of IL-12 are to
induce IFN-g production and to favor
potent and long-lasting Th1 and CTL
responses (Trinchieri et al., 2003).
Because of these functions, IL-12 can
have a strong antitumor effect. Under
normal, unmanipulated conditions, hema-
topoietic cells in the tumor mass do not
produce IL-12. Moreover, whereas
macrophages and DCs of nonmalignant
tissues are potent producers of IL-12
when stimulated through Toll-like recep-
tors (TLRs) or TNF family receptors,
TAMs and DCs are unable to produce
IL-12 and other proinflammatory cyto-
kines when exposed to the same stimuliCancer Cell 1(Vicari et al., 2002). IL-23 is composed of
the same IL-12b chain covalently linked
to the unique IL-23a (p19) chain (Trinchieri
et al., 2003). IL-23 signals through
a receptor composed of IL-12Rb1 and
IL-23R that also functionally links to Tyk2
and Jak2 but activates STAT3/STAT3,
STAT3/STAT4, and in part STAT5/STAT5
dimers (Trinchieri et al., 2003). The
expression of IL-12 and IL-23 is controlled
at multiple levels. The genes encoding the
two chains of these cytokines need to be
simultaneously expressed in producing
cells. The common IL-12b chain is nor-
mally produced in large excess, but the
production of both heterodimers is limited
not only by the amount of each chain but
also by many posttranscriptional and
posttranslational mechanisms.
IL-12 and IL-23 share some functions.
However, it is now well established that
IL-23, through its ability to induce
STAT3, is involved in inducing IL-17
production and the pathogenic potential
of the recently described Th17 cells (Trin-
chieri et al., 2003). Moreover, in contrast
to the antitumor role of IL-12, production
of IL-23 within the tumor has a tumor-
promoting effect in both chemical carci-
nogenesis and transplantable tumor
models, in part by preventing activation
and function of CTLs (Langowski et al.,
2007). At the time, the protumor potential
of IL-23 was unexpected because of its
role in driving Th17 cells that trigger tissue
destruction and are associated with auto-
immune conditions.
Kortylewski et al. (2009) now provide
a novel framework with which we can
revisit current knowledge of the complex
molecular regulation by STAT3 and IL-235, February 3, 2009 ª2009 Elsevier Inc. 81
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Functions
STAT3 is overexpressed in many tumor types, favoring tumor growth and dissemination but also recruiting
hematopoietic cells and inhibiting the maturation and function of tumor-associated macrophages (TAMs)
and dendritic cells (DCs). In particular, the transcription of several proinflammatory genes such as the
two genes encoding IL-12 in DCs is indirectly inhibited through the STAT3-dependent induction of the tran-
scriptional suppressorEtv3andSbno2. Conversely, the transcriptionof the Il23ageneand theproductionof
IL-23aredirectly inducedbySTAT3 inTAMs.Tumorscontain a largenumberof immunosuppressiveFoxp3+
regulatory T cells (Tregs) that, unlike Tregs in other organs, express IL-23R and are functionally activated by
IL-23.Deletion of STAT3 in hematopoietic cells induces the antitumor cytokine IL-12while inhibiting thepro-
tumor cytokine IL-23 and the IL-23-dependent activation of Tregs, resulting in delayed tumor growth.(Figure 1). They report that IL-23, but not
IL-12, is spontaneously produced by
TAMs in several transplantable mouse
tumor models. Surprisingly, inactivation
of STAT3 in hematopoietic cells results
in the repression of IL-23 production by
TAMs but activation of IL-12 production
in DCs. The authors clearly demonstrate
that, together with RelA (p65, an NF-kB
component), STAT3 directly binds and
activates the IL-23a (p19) promoter.
NF-kB, through both RelA and c-Rel,
was previously known to regulate the
production of all three IL-12/23 chains,
but a direct role for STAT3 in their activa-
tion had not been reported. A similar
mechanism might occur when prosta-
glandin E2, which may also act though
STAT3, inhibits IL-12 production while
inducing IL-23 in DCs (Khayrullina et al.,
2008). Also, nonphosphorylated STAT3
has been shown to bind to RelA-p50
dimers to induce a subset of genes such
as Rantes (Yang et al., 2007). It would
therefore be interesting to determine82 Cancer Cell 15, February 3, 2009 ª2009 Ewhether this noncanonical mechanism of
NF-kB- and STAT3-induced gene tran-
scription could be operational for IL-23.
The IL-23-inducing effect of STAT3
observed by Kortylewski et al. was unan-
ticipated because IL-10 inhibits both
IL-12 and IL-23 production through
STAT3 signaling. Why does STAT3
signaling promote IL-23 production under
these circumstances but mediate a more
global anti-inflammatory effect in other
contexts? The inhibition of gene transcrip-
tion by IL-10-induced STAT3 has been
shown to be mediated indirectly through
the ETS family transcriptional suppressor
ETV3 and the helicase family corepressor
SBNO2 rather than direct promoter
binding to suppressed genes (e.g., Il12a
and Il12b) (El Kasmi et al., 2007). IL-10
induces these repressor factors, but other
STAT3-inducing cytokines suchas IL-6 do
not. Differential responses between IL-10
and other STAT3-inducing cytokines
have been attributed to suppressor of
cytokine signaling 3 (SOCS3), which islsevier Inc.induced by high levels of STAT3 and
affects function of the IL-6 receptor chain
gp130 but not the IL-10 receptor. It is
therefore noteworthy that TAMs and DCs
can be driven to produce IL-12 with an
antitumor effect by inhibiting IL-10 alone,
suggesting that even if various factors
induce STAT3 activation and expression
in the tumor microenvironment, its anti-
inflammatory effect critically depends
upon IL-10 (Vicari et al., 2002).
Kortylewski et al. also observed an anti-
tumoreffect ofSTAT3 inhibition thatwas in
part due to decreased activity of Foxp3+
Tregs. Indeed, they showed that tumor-
associated Tregs, unlike spleen Tregs,
express IL-23 receptor (IL-23R) and are
activated in response to IL-23, resulting
in higher expression of Foxp3 and IL-10
production. This is surprising because in
other settings, STAT3 activation by IL-6
or IL-21 in TGF-b-exposed T cells induces
downregulation of Foxp3 and upregula-
tion of the transcription factor RORgT
leading to induction of IL-17-producing
Th17 cells (Wei et al., 2008). STAT3 in the
context of IL-23 signaling might also be
expected todrive respecialization of Tregs
to a Th17 phenotype. Although very few
Th17 cells were detected in the tumor
models studied, their development was
completely dependent on STAT3. Several
explanations canbe evoked to explain this
Treg-biased profile in the context of IL-23:
for example, SOCS3 may limit IL-6 and
IL-21 signaling through STAT3 in tumor-
infiltrating T cells, thus preventing Th17
conversion, while IL-23-induced STAT5
activation persists. Alternatively, other
elements (e.g., excess of TGF-b, IFN-g,
and/or IL-2 or lack of IL-1) in the tumor
microenvironment may affect the ability
of IL-23 and/or IL-6 to induce Th17 differ-
entiation (Wei et al., 2008).
In conclusion, the inflammatory tumor
microenvironment appears quite distinct
from that of autoimmune tissues, where
Tregs or Th17 cells predominate. The
Kortylewski et al. study sheds light on
the important question of how STAT3
and IL-23 may differentially contribute to
each form of inflammation.
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The idea that stem cells or their close
derivativesmight underlie tumor formation
has a long history but has come to the fore
with the advent of modern stem cell
biology. We now know that, for a variety
of tumors, there is an essential subpopula-
tion of cells that maintains the growth of
neoplastic tissue and can initiate new
tumors in vivo when transplanted into
a receptive host. These tumor-propa-
gating cells (TPCs) can resemble normal
tissue stem cells in their marker expres-
sion and their ability to self-renew and
produce differentiated progeny. For
a given tumor type, defining its constituent
TPCs is of paramount importance—first to
identify and target them to combat tumor
growth, and second to understand their
etiology and find ways to prevent tumor
formation. Do TPCs arise from normal
stem cells that go awry and proliferate
uncontrollably, disregarding regulatory
mechanisms that keep them in check, or
do they arise from later-stage progenitor
cells that revert to acquire stem-like
features? These two views of cancer
formation—reminiscent of the literary
characters of Dorian Gray, who didn’t
age, and Benjamin Button, who was born
old and grew young—are an active pointTrinchieri, G., Pflanz, S., and Kastelein, R.A. (2003).
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tumor-propagating cells (TPCs) that
colleagues show that in an animal
nd have properties distinct from neu
of debate. Recent studies indicate that
mutations in the stem cell compartment
more readily phenocopy colon cancer
(Barker et al., 2008). However the same
might not be true for cancers in other
tissues.
Medulloblastomas are the most com-
mon pediatric brain tumors. They occur in
the cerebellum, a brain region involved in
integrating sensory perception and move-
ment control. The cerebellum forms from
twomajor germinal regions, the ventricular
zone and the external granular layer
(Figure 1). The most abundant cell in the
brain, the cerebellar granule neuron, arises
from granule neuron precursors (GNPs) in
the external granular layer, largely during
the early postnatal period.
The remarkable expansion of GNPs is
governed principally by the growth factor
Sonic hedgehog (Shh) (Kenney et al.,
2003). The signaling cascade is initiated
by Shh binding to the cell surface receptor
Patched (Ptc). A key player in the cascade
is a G protein-coupled receptor-like mole-
cule called Smoothened (Smo). In the ab-
sence of Shh, Ptc inhibits the activity of
Smo. Shh binding to Ptc relieves its inhibi-
tion, andSmocansignal downstream.The
targets of Smo include Gli transcription
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are critical for their growth. In this
model of medulloblastoma, TPCs
ral stem cells.
factors, which then translocate to the
nucleus and initiate transcription.
Approximately 25% of medulloblas-
tomas result from inappropriate activation
of Shh signaling, and a subset of human
medulloblastomas harbor mutations of
the Ptc gene (Zurawel et al., 2000). A
useful model of medulloblastoma is the
Ptc+/ mutant mouse. Ptc haploinsuffi-
ciency increases proliferation of neural
stem cells (Galvin et al., 2007), and 15%–
20% of Ptc+/mice develop medulloblas-
tomas (Goodrich et al., 1997).
Read et al. (2009) examined medullo-
blastomas derived from Ptc+/ mice.
Using fluorescence-activated cell sorting
(FACS) with cell surface markers, they
separated subpopulations of live cells
and then stereotaxically injected these
into SCID/beige mouse cerebella to
examine whether they could form tumors.
Surprisingly, the investigators found that
medulloblastomas were not propagated
by cells expressing the neural stem cell
(NSC) marker CD133, leading them to
search for other candidate markers. A
prior study had described CD15, also
known as Lewis X (LeX) or stage-specific
embryonic antigen-1 (SSEA-1), as a
marker of forebrain NSCs and progenitor
15, February 3, 2009 ª2009 Elsevier Inc. 83
